Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 611-619

  Koç, Esra ^a   Küçükgüzel, Ş Güniz ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Anti inflammatory; Nitric oxide; NO NSAID

Indexed keywords

2 (7 TRIFLUOROMETHYLQUINOLIN 4 YL AMINO)BENZOIC ACID N' (2 NITROOXYPROPIONYL)HYDRAZIDE; 2 NITROOXYL 1 NITROOXYMETHYETHYL 2 (3 CHLORO2 METHYLPHENYLAMINO)BENZOIC ACID; 3 [4 [2 FLUORO ALPHA METHYL (1,1' BIPHENYL) 4 ACETYLOXY] 3 METHOXYPHENYL] 2 PROPENOIC ACID 4 NITROOXY BUTYL ESTER; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; FLOCTAFENINE; FLUFENAMIC ACID; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN; INDOMETACIN; NAPROXCINOD; NAPROXEN; NCX 2216; NCX 4015; NCX 4023; NITRIC OXIDE; NITRIC OXIDE DONOR NONSTEROID ANTIINFLAMMATORY AGENT; NITRODICLOFENAC; NITROKETOPROFEN; NITRONAPROXEN; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TEPOXALIN; TOLPHENAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZLR 8;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; IMMUNOCOMPETENCE; INFLAMMATORY DISEASE; NONHUMAN; PAW EDEMA; PORTAL HYPERTENSION; PSORIASIS; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; STOMACH INJURY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; HUMANS; NITRIC OXIDE;

EID: 67649888575     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167556     Document Type: Article

References (35)

1. Griffith, O.W.; Stuehr, D.J. Nitric oxide synthases: properties and catalytic mechanism." Annu. Rev. Physiol., 1995, 57, 707-36.
2. Keeble, J.E.; Moore, P.K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs." Br. J. Pharmacol., 2002, 137, 295-10.
3. Amir, M.; Kumar, S. Anti-inflammatory and gastro sparing activity of some new indomethacin derivatives." Arch. Pharm. (Weinheim), 2005, 338, 24-31.
4. Narayana, B.; Vijaya, R.K.K.; Ashalatha, B.V.; Kumari, N.S. Synthesis of some new 2-(6-methoxy-2-naphthyl)-5-aryl-1,3,4-oxadiazoles as possible non-steroidal anti-inflammatory and analgesic agents." Arch. Pharm. (Weinheim), 2005, 338, 373-7.
5. Amir, M.; Kumar, S.; Javed, S.A. Non-carboxylic analogues of naproxen: design, synthesis, and pharmacological evaluation of some 1,3,4-Oxadiazole/Thiadiazole and 1,2,4-Triazole derivatives." Arch. Pharm. (Weinheim), 2007, 340, 577-85.
6. Nargund, L.V.G.; Reddy, G.R.N.; Hariprasad, V. Antiinflammatory activity of substituted 1,3,4-oxadiazoles." J. Pharm. Sci. 1994, 83, 246-8.
7. Küçükgüzel, Ş.G.; Küçükgüzel, I.; Tatar, E.; Rollas, S.; Şahin, F.; Güllüce, M.; De Clercq, E.; Kabasakal, L. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents Eur. J. Med. Chem., 2007, 42, 893-01.
8. Amir, M.; Kumar, S. Synthesis of some new 2-(2-fluoro-4-biphenylyl) propionic acid derivatives as potential anti-inflammatory agents. Pharmazie, 2005, 60, 175-80.
9. Abbas, S.E.; Abou-Youssef, H.E.; El-Taliawi, G.M.; Hassan, A.B. Synthesis of certain 1,3,4-oxadiazole derivatives of expected antiinflammatory activity. Egypt. J. Pharm. Sci., 1991, 32, 515-27.
10. Amir, M.; Kumar, S. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino)phenyl]acetic acid derivatives. Eur. J. Med. Chem., 2004, 39, 535-45.
11. Bhandari, S.V.; Bothara, K.G.; Raut, M.K.; Patil, R.A.A.; Sarkate, A.P.; Mokale, V.J.; Design, Synthesis and Evaluation of Antiinflammatory, Analgesic and Ulcerogenicity studies of Novel SSubstituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic Derivatives. Bioorg. Med. Chem., 2008, 16, 1822-31.
12. Boschelli, D.H.; Connor, D.T.; Hoefle, M.; Bornemeier, D.A.; Dyer, R.D. Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg. Med. Chem. Lett., 1992, 2, 69-72.
13. Metwally, K.A., Yaseen S.H., El-Sayed M. L., El-Fayomi H.M., El-Sadek M. E. Non-carboxylic analogues of arylpropionic acids: Synthesis, anti-inflammatory activity and ulcerogenic potential. Eur. J. Med. Chem, 2007, 42, 152-60.
14. Hegazy, G.H.; Taher, A.; El-Zaher, A.A. Synthesis of Some Floctafenine Derivatives of Expected Anti-inflammatory/Analgesic Activity. Arch. Pharm. (Weinheim), 2005, 338, 378-84.
15. Cheng H.F.; Harris R.C. Renal effects of non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr. Pharm. Des., 2005, 11, 1795-804.
16. Bor S. Sogut Agaci Yapragindan Zararsiz Nonsteroidlere: Gastroenterolojinin Dusu Gerceklesiyor mu? Guncel. Gastroentoloji, 2004, 8/3, 236.
17. Abadi A.H.; Hegazy G.H.; El-Zaher A.A. Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and antiinflammatory agents. Bioorg. Med. Chem., 2005, 13, 5759-65.
18. Ranatunge R.R., Augustyniak M.E.; Dhawan V.; Ellis J.L.; Garvey D.S.; Janero D.R.; Letts L.G.; Richardson S.K.; Shumway M.J.; Trocha A.M.; Young D.V.; Zemtseva I.S. Synthesis and antiinflammatory activity of a series of N-substituted naproxen glycolamides: Nitric oxide-donor naproxen prodrugs. Bioorg. Med. Chem., 2006, 14, 2589-99.
19. Hawkey C.J.; Jones J.I,; Atherton C.T.; Skelly M.M.; Bebb J.R.; Fagerholm U.; Jonzon B.; Karlsson P.; Bjarnason I.T. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut, 2003, 52, 1537-42.
20. http://www.drugdevelopment-technology.com/projects/azd3582/HCT 3012-COX-inhibiting nitric oxide-donator (CINOD) for relief of pain and inflammation.
21. Ziakas G.N.; Rekka E.A.; Gavalas A.M.; Eleftheriou P.T.; Tsiakitzis K.C.; Kourounakis P.N. Nitric oxide releasing derivatives of tolfenamic acid with anti-inflammatory activity and safe gastrointestinal profile. Bioorg. Med. Chem., 2005, 13, 6485-92.
22. Bengmark S. Curcumin, an atoxic antioxidant and natural NFκB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: A shield against acute and chronic diseases. JPEN. J. Parenter. Enteral. Nutr., 2006, 30, 45-51.
23. Charlier C.; Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem., 2003, 38, 645-59.
24. Wey S.J.; Augustyniak M. E.; Cochran E.D.; Ellis J. L.; Fang X.; Garvey D.S.; Janero D. R.; Letts L. G.; Martino A. M.; Melim T. L.; Murty M. G.; Richardson S. K.; Schroeder J. D.; Selig W. M.; Trocha A. M.; Wexler, R.S.; Young D. V.; Zemtseva I. S.; Zifcak B. M. Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J. Med. Chem., 2007, 50, 6367-82.
25. Chiroli V.; Benedini F.; Ongi Eni; Soldato P.D. Nitric oxidedonating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur. J. Med. Chem., 2003, 38, 441-6.
26. Fiorucci S.; Santucci L.; Gresele P.; Faccino R.M.; Soldato P.D.; Morelli A. Gastrointestinal safety of NO-aspirin (NCX 4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology, 2003, 124, 600-7.
27. Carini M.; Aldini G.; Orioli M.; Piccoli A.; Tocchetti P.; Facino R.M. Chemiluminescence and LC-Ms/MS analyses for the study of nitric-oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J. Pharm. Biomed. Anal., 2004, 16-35(2), 277-87.
28. Carini M.; Aldini G.; Orioli M.; Piccoli A.; Rossoni G; Maffei Facino R. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci., 2004, 74, 3291-305.
29. Napoli, C.; Ignarro, L.J. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 97-123.
30. Wallace, J.L.; Ignarro, L.J.; Fiorucci, S. Potential cardioprotective actions of no-releasing aspirin. Nat. Rev. Drug. Discov. 2002, 1, 375-82.
31. Wallace J.L.; Muscara M.N.; de Nucci G.; Zamuner S.; Cirino G.; del Soldato P.; Ongini E. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-α-methyl- [1,1′-biphenyl]-4-acetyloxy)- 3-methoxyphenyl]-2-propenoic acid 4- nitrooxy butyl ester]. J. Pharmacol. Exp.Ther., 2004, 309, 626-33.
32. Jiao H.; Xu F.; Zhang Z.; Tian Y.; Jiang Z.; Zhang L. Simultaneous determination of ZLR-8 and its active metabolite diclofenac in dog plasma by high-performance liquid chromatography. Biomed. Chromatogr., 2007, 21, 382-8.
33. Li R.W.; Zhang Y.H.; Ji H.; Yu X.L.; Peng S.X. Synthesis and anti-inflammatory analgesic activities of phenylfuroxan-coupled diclofenac. Acta Pharm. Sin., 2002, 37, 27-32.
34. Engelhardt F. C.; Shi Yao-Jun; Cowden C.J.; Conlon D.A.; Pipik B.; Zhou G.; McNamara J.M.; Dolling Ulf-H. Synthesis of a NOreleasing prodrug of rofecoxib. J. Org. Chem., 2006, 71, 480-91.
35. Laleman W.; Landeghem L. V.; Elst I. Van Der; Zeegers M.; Fevery J.; Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology, 2007, 132, 709-19.